Advertisement

Role of single nucleotide polymorphisms (SNPs) in common migraine

  • Sukhvinder KaurEmail author
  • Arif Ali
  • Uzair Ahmad
  • Yaser Siahbalaei
  • A. K. Pandey
  • Balkirat Singh
Open Access
Review
  • 33 Downloads

Abstract

Single nucleotide polymorphisms (SNPs) may act as biological markers, as they can relate to the genes that are associated with various complex diseases such as heart diseases, diabetes, cancer, schizophrenia, blood pressure, migraine, and Alzheimer. These SNPs mostly locate within a gene or in a regulatory region near a gene and can affect the gene’s function to play a more direct role in disease. Hence, SNPs allow scientists to develop candidate drug therapy by evaluating an individual’s genetic makeup to develop a particular disease. Gene-gene interactions generally complicate migraine and its genetics and further gene-environmental interactions that often misguide the true defying causes of this disease. Due to its complex nature, it is difficult for scientists to reveal a complete list of SNPs or even all the genes that are related with the pathogenesis of this disease. Nowadays, much work has been done in this direction and new variants of migraine are being constantly identified. In this review article, the role of various SNPs reported to be disease-associated in published migraine GWAS has been discussed. To understand the molecular mechanisms of migraine attack by identifying new genetic variants of migraine can be a key to develop new therapeutic strategies in the future.

Keywords

Migraine Genetics Single nucleotide polymorphisms Genome-wide association studies (GWAS) 

Abbreviations

ACE

Angiotensin I-converting enzyme

AJAP1

Adherens junction-associated protein 1

ASTN2

Astrotactin 2

C7orf10

Chromosome 7 open reading frame 10

CACNA1A

Calcium voltage-gated channel subunit alpha1 A

cAMP

Cyclic adenosine monophosphate

CEP104

Centrosomal protein 104

CGRP

Calcitonin gene-related peptide

CREB

cAMP response element binding

CREM

cAMP-responsive element modulator

CSD

Cortical spreading depression

CVD

Cardiovascular disease

DFFB

DNA fragmentation factor subunit beta

EAAT2

Excitotoxic amino acid transporter 2

ESR1

Estrogen receptor 1

FHL5

Four and a half LIM domains protein 5

GLT-1

Glutamate transporter 1

GWAS

Genome-wide association study

HMG

Hydroxy methyl glutarate

KCCN3

Potassium calcium-activated channel subfamily N member 3

LRP1

Lipoprotein receptor 1

MA

Migraine with aura

MEF2D

Myocyte enhancer factor 2D

MMP16

Matrix metalloproteinase16

MO

Migraine without aura

MT3-MMP

Membrane-type-3 matrix metalloproteinase

MTDH

Metadherin

MTHFR

Methylenetetrahydrofolate reductase

NgR1

Nogo-66 receptor 1

NMDA

N-methyl-d-aspartate receptor

PGCP

Plasma glutamate carboxypeptidase

PGR

Progesterone

PHACTR1

Phosphatase and actin regulator 1

PP1

Protein phosphatise

PRDM16

PR domain containing 16

SLC1A2

Solute carrier family 1 member 2

SNP

Single nucleotide polymorphism

TCC

Trigemino-cervical complex

TG

Trigeminal ganglion

TGFBR2

Transforming growth factor β receptor 2

TGF-β

Transforming growth factor beta

TP73

Tumor protein P73

TRPM8

Transient receptor potential cation channel, subfamily M, member 8

TSPAN2

Tetraspanin 2

Introduction

Migraine is a common, chronic, polygenic neurovascular disorder in which both genetic and environmental factors play their roles. This disease affects about 15% of the population overall. The prevalence of migraine in women (18%) is higher when compared with men (6%), with attacks lasting from a few hours to some days [1]. The higher prevalence in women is typically attributed to hormonal fluctuations especially estrogen. Migraines typically begin during puberty or between the ages of 35 and 45 years [2, 3]. Migraine is a disabling disorder, which reduces the quality of life and significantly affects the ability to work and moreover results in higher cost and greater health care resource utilization [4, 5, 6]. Migraine can be classified into two types on the basis of aura: migraine without aura (MO) and migraine with aura (MA) and up to one-third of patients experience an aura prior or during the headache attacks. In migraine with aura (MA), patients can show transient facial neurological symptoms that mostly precede or in some cases accompany the headache. A premonitory phase having symptoms of depression, cravings for particular foods, fatigue, hyper or hypoactivity along with repetitive yawning, and neck stiffness is reported, which occur hours or days before the headache, and a headache resolution phase [7]. Migraine without aura (MO) is characterized by headache with specific features and associated symptoms such as unilateral location, pulsating quality, moderate, or severe pain intensity. During headache nausea, vomiting, photophobia, and phonophobia can occur [8]. The main criteria for the diagnosis of migraine with and without aura by the International Headache Society in 2013 [9] are given in Table 1.
Table 1

International classification of headache disorders 3rd edition [9]

Migraine without aura (MO)

Migraine with aura (MA)

Diagnostic criteria

  A. At least five attacks fulfilling criteria B–D

  B. Headache attacks lasting 4–72 h (untreated or unsuccessfully treated)2,3

  C. Headache has at least two of the following four characteristics:

 1. Unilateral location

 2. Pulsating quality

 3. Moderate or severe pain intensity

 4. Aggravation by or causing avoidance of routine physical activity (e.g., walking or climbing stairs)

  D. During headache at least one of the following:

 1. Nausea and/or vomiting

 2. Photophobia and phonophobia

  E. Not better accounted for by another ICHD-3 diagnosis

Diagnostic criteria

A. At least two attacks fulfilling criteria B and C

B. One or more of the following fully reversible aura symptoms:

1. Visual

2. Sensory

3. Speech and/or language

4. Motor

5. Brainstem

6. Retinal

C. At least two of the following four characteristics

1. At least one aura symptom spreads gradually over 5 min, and/or two or more symptoms occur in succession

2. Each individual aura symptom lasts 5–60 min

3. At least one aura symptom is unilateral

4. The aura is accompanied, or followed within 60 min, by headache

D. Not better accounted for by another ICHD-3 diagnosis, and transient ischemic attack has been excluded

Migraine and its genetics

Migraine has a direct impact on the lives of millions of people worldwide, and for most of them, there is still no effective treatment. Nowadays, genome-wide association studies have emerged as an important mean to uncover the genetic variants of complex disorders such as migraine. Whole exome sequencing is potentially an effective tool to identify coding variants underlying human diseases like migraine. In several GWAS, common SNPs related with migraine have proved to be very useful. These SNPs even help in understanding the role of the glutamatergic system, sensitization of nociceptive nerve endings, and cortical spreading depression in the pathogenesis of migraine. Despite this fact that GWAS have revealed new candidate genes and various SNPs related with them that could be the reason for migraine pathogenesis, still, the outcomes from previous findings have not brought us closer to understand its molecular and genetic bases. The reason behind this may be the multi-genetic and multi-factorial nature of this disorder. Further, more studies should be done for building a gene profile of the complex common migraine disorder which may provide new drug targets.

To better understand the genetics of migraine, approaches to study candidate genes and linkage studies are also widely used. For a large number of genes and its related SNPs, various replication studies have been done and these studies either confirmed or disproved the association. A criterion using the combination of physiological functions with genomic associations is widely used to find out the most possible variants related with common migraine pathogenesis. On this basis, three different groups of genes including neurological, hormonal, or vascular pathways have been identified for this disorder [10, 11]. Under the neurological group, genes that are involved with expression or control of ion channels (CACNA1A, KCCN3, Sodium-Potassium-ATPase), genes responsible for the synthesis/release and binding of neuropeptides (CGRP protein, glutamate), and the genes with functional effects in dopamine and serotonergic pathways have been reported. The second group of vascular genes is mostly functional in the regulation of blood pressure, endothelial cell expression, vasoconstriction, and vasodilation (MTHFR, ACE). Vascular genes are responsible for migraine particularly migraine with aura overlap with the genes that have a role in elevated risk of stroke and heart disease as a significant co-morbidity with risk for stroke and depression [12]. The third group of genes is typically related with women that can describe the sex-biased distribution of migraine. Genes that can regulate hormonal pathways in females and menstrual migraine include mostly those which can control estrogen and progesterone (ESR1, PGR) levels [13].

Migraine and its SNPs

Genome-wide association studies of migraine (MA and MO), family clustering, and twin studies have identified various migraine-associated common genetic variants [14, 15]. The first large migraine meta-analysis was performed by Anttila et al. [16] that had 29 studies with 23,285 migraineurs and 95,425 controls. In that study, 12 single nucleotide polymorphisms (SNPs) were revealed that were related with migraine susceptibility. Recently, a GWAS [17] had revealed 38 genomic variants mostly found in humans (with > 5% allele frequency) which can affect migraine risk. Previous studies [18, 19] have found additional variants that make the total number of genomic regions related with migraine as high as 47. These variants hint towards a remarkable progress in this direction and provide causes for optimism that the key mechanisms for this disorder can finally be understood. Thus, migraine-related GWAS and reported meta-analyses found different SNPs for this disease, which can be further classified into five pathways [20] on the bases of function:
  • Genes involved in glutamatergic neurotransmission—rs1835740 in MTDH, rs11172113 in LRP1, and rs3790455 in MEF2D

  • Genes for synapse development and neuroplasticity—rs6478241 in ASTN2, rs1320832 in FHL5

  • Genes for pain sensitivity—rs10166942 in TRPM8

  • Genes for metalloproteinases—rs10504861 near to MMP16, rs10915437 near to AJAP1, rs12134493 near to TSPAN2

  • Genes responsible for vascular system and metabolism—rs4379368 in C7orf10, rs2651899 in PRDM16, rs9349379 in PHACTR1, rs7640543 near to TGFBR2

In this review, the most common genes and their variants involved as biomarkers for migraine have been discussed and listed in Table 2.
Table 2

Variants identified in common form of migraine and replicated in various studies

SNPs

Chromosome locus

Gene

Biochemical markers

rs1835740

8q22.1

MTDH

Glutamate

rs1801133

rs1801131

1p36.3

MTHFR

Homocysteine

rs11172113

12q13.3

LRP1

NMDA glutamate

rs10166942

2q37

TRPM8

Pain sensor protein

rs2651899

1p36.32

PRDM16

TGF-β signaling

rs4379368

7p14

C7orf10

Glutaric acid

rs10504861

8q21

MMp16

MT3-MMP protein

rs10915437

1p36

AJAP1

DFFB, TP73, and CEP104 protein

rs12134493

rs2078371

1p13

TSPAN2

Transmembrane protein

rs13208321

6q16

FHL5

CREM, CREB

rs3790455

1q22

MEF2D

rs7640543

3p24.1

TGFBR2

rs9349379

6p21

PHACTR1

PP1

rs6478241

9q33.1

ASTN2

rs1835740

This SNP, present on 8q22.1 chromosomal region, is located in a 27 kb haplotype block between genes MTDH (metadherin, astrocyte elevated gene 1) and PGCP (plasma glutamate carboxypeptidase). This variant is mainly responsible for glutamate homeostasis and best known for harboring different genes involved in glutamate metabolism and transport. This SNP regulates the expression of MTDH gene and hence indirectly regulates the expression of the glutamate transporter gene SLC1A2 which is also known as EAAT2 or GLT-1 that further encodes a major glutamate transporter protein in the brain. It has been reported in various studies that by increasing the release of glutamate or reduction in uptake of glutamate increase the risk of migraine attacks [21, 22, 23]. In astrocytes, MTDH downregulates GLT-1, the gene encoding the major glutamate transporter protein. SNPs in MTDH gene thus can contribute towards understanding the role of glutamate in this disorder. Higher levels of glutamate increase the susceptibility towards cortical spreading depression. Glutamate is one of the major excitatory neurotransmitters in the CNS and therefore has an important role to play in the mediation of excitatory synaptic transmission [24, 25, 26]. In the migraine pain pathway, the anatomic structures contain glutamate-positive neurons which include the trigeminal ganglion (TG), thalamus, and the trigemino-cervical complex (TCC) [27, 28]. Migraineurs have higher levels of glutamate and glutamine in their cerebrospinal fluids on comparing with controls and also shown a positive correlation between glutamate levels and mean headache scores [29, 30]. This SNP in MTDH gene increases the interest in glutamatergic pathways in migraine but can explain only a small fraction of the overall genetic variance.

rs1801133 and rs1801131

The MTHFR gene, on chromosome 1p36, has 11 exons of ~ 17 kb in size [31]. A common SNP (C677T) in MTHFR gene encodes for amino acid valine (Val) instead of alanine (Ala) at position 222. Migraineurs with the valine instead of alanine amino acid due to this SNP may exhibit a significantly reduced MTHFR enzyme activity which is 30% in the Val/Val homozygous state as compared to 65% in the Ala/Val heterozygote [32]. If the patients further have a low intake of dietary folate, then this reduced activity of MTHFR gene can result in mild elevation in plasma homocysteine levels [33]. Mild hyper homo-cysteinemia has been associated with an increased risk of cardiovascular diseases (CVD) that include cerebral, coronary, and peripheral vascular diseases [34]. It is reported that homocysteine may act like an excitatory amino acid in migraine pathophysiology. Homocysteine can cause vasodilation or temporary thrombosis of cerebral blood vessels and thus leading to reduce the supply of oxygen into the brain [35, 36]. Interestingly, an increased risk of ischemic stroke is also associated with the migraine disorder itself, particularly with MA in some studies [37]. Further, cortical spreading depression (CSD) in MA, with changes in cerebral blood flow and headache, can also occur along with a stroke episode [38]. On the basis of the co-morbidity between migraine and stroke and with the role of homocysteine in disturbing the cerebro-circulatory system, it is possible that the MTHFR C677T SNP may represent an important genetic variant for the vascular pathophysiologies of migraine representing both neurovascular conditions.

Similarly, rs1801131 and A1298C SNP can cause a point mutation in MTHFR gene at position 1298 and are responsible for encoding glutamine instead of alanine residue [39]. This polymorphism A1298C may affect the enzyme activity of MTHFR as well as folate concentrations, although less than those reported in SNP C677T. Additionally, A1298C SNP is located within the regulatory domain of MTHFR gene. In the previous studies, it has been shown that individuals homozygous only for the A1298C SNP do not report higher homocysteine levels in serum than that of controls but those who are heterozygous both for the A1298C and C677T SNPs tend to have a similar biochemical profile with C677T homozygotes, showing an increase in homocysteine levels and a decrease in folate concentrations in serum [40]. Hence, the investigation of MTHFR polymorphisms and their effects on metabolic pathway of folate has been considered as an interesting topic for research in recent years.

rs11172113

rs11172113, a SNP on chromosome 12q13.3, is located in the first intron of LRP1 gene. This SNP is responsible for the lipoprotein receptor LRP1 [41], which further showed interaction with neuronal glutamate receptors in the brain. Hence, this variant also shares a common link with the glutamate pathway via interaction of LRP1 receptors with NMDA glutamate receptors in migraine. Both previous findings [15, 16] have discussed the role of glutamate in the pathophysiology of migraine and integrated well with various pharmacological approaches that can further target glutamate receptors for migraine treatment [26].

rs10166942

rs10166942, a SNP on chromosome 2q37, is located close to the gene TRPM8 at the transcription start site. TRPM8 gene encodes a sensor protein for a cold and cold-induced burning pain [42] that is primarily expressed in sensory neurons and the dorsal root ganglion in the brain [43]. It has been investigated that TRPM8 can be a target in various animal models with neuropathic pain. As both migraine and neuropathic pain share some features, the role for TRPM8 variant in this disease as well as its relation between both pain syndromes can be an interesting topic in future for research scientists [44, 45].

rs2651899

rs2651899 SNP, located on chromosome 1p36.32, is in the first intron of PRDM16 (PR domain containing 16) gene. This gene codes for a zinc finger transcription factor, supposed to be associated with differentiation of brown adipose tissue along with repression of TGF-β (transforming growth factor beta) signaling [46, 47], but the role of this gene is still unclear in migraine. More case-control studies with a reasonable number of individuals from different geographical regions are needed to explore the relationship of this SNP with migraine.

rs4379368

rs4379368 SNP, on chromosome 7p14, is found within an intron in the transcript of the C7orf10 gene and encodes enzyme succinic HMG coenzyme A transferase. It has been reported that mutations in c7orf10 can cause glutaricaciduria type III which is a rare metabolic abnormality in individuals leading to persistent excretion of glutaric acid [48]. Different SNPs in this gene may differentially control the transcription and/or RNA processing and as a result affecting the risk of migraine [49].

rs10504861

rs10504861, a SNP located on chromosome 8q21, is 200 kb away from the matrix metalloproteinase MMP16 gene. Metalloproteinase is an extended family of protease enzymes that are responsible for the breakdown of extracellular matrix in various normal physiological processes. This SNP has been linked with an elevated incidence of migraine without aura (MO) in genome-wide association studies (GWAS), as the protein encoded by MMP16 gene is associated with the cleavage of the low-density lipoprotein receptor protein (LRP1) [50]. A SNP within LRP1 (rs11172113) has already been revealed to be associated with migraine in a genome-wide association study (GWAS). Various studies have recently shown that MT3-MMP encoded by this gene is supposed to cause basal NgR1 (Nogo-66 receptor) shedding in cortical neurons and to increase axonal and synaptic plasticity [51]. Although for the mechanism showing association of MMP16 to migraines, no conclusive evidence exists so far, these two findings may offer plausible reasons for the biological implication of rs10504861 SNP in migraine pathology [14, 52]. More case-control studies are needed to associate this SNP with migraine.

rs10915437

The SNP rs10915437, on chromosome 1p36, is present approximately 500 kb telomeric from the adherens junction-associated protein 1 (AJAP1) gene and almost 300 kb centromeric from a gene cluster that encodes the apoptosis-related proteins DFFB and TP73 as well as centrosomal protein CEP104. AJAP1 has been related with tumor invasion and supposed to control the regulation of metalloproteinase activity and is expressed in the brain [53]. Hence, indirectly, this SNP may link with the migraine pathology and much work is required to relate this association.

rs12134493

The SNP rs12134493 is on chromosome 1p13 and located 87 kb 5′upstream of the tetraspanin 2 (TSPAN2) gene. This gene encodes a four trans-membrane protein which causes the modulation of development, activation, growth, and movement of cells via the mediation of signal transduction. Esserlind et al. reported another SNP (rs2078371) that is located near gene TSPAN2 in a GWAS and had shown the genome-wide significance of association with migraine in Danish and Icelandic populations and hence supported the indirect role of this SNP in migraine [14].

rs13208321

The SNP rs13208321, present on chromosome 6q16, is within the four and a half LIM domains protein 5 (FHL5) gene. This SNP is reported to influence protein function in cells. FHL5 gene can encode a transcription factor which further regulates cAMP-responsive elements CREM and CREB [54], and those have a role to play in synaptic plasticity associated with migraine and memory formation [55, 56].

Another study by Freilinger et al. [57] revealed associations of migraine with four new SNPs and also replicated the findings of previously related associations with TRMP8 and LRP1 genes. These new variants with the strongest association at the respective locus were rs3790455 (MEF2D) on chromosome1q22, rs7640543 (TGFBR2) on chromosome 3p24.1, rs9349379 (PHACTR1) on chromosome6p21, and rs6478241 (ASTN2) on chromosome 9q33.1. Myocyte enhancer factor 2D (MEF2D), a transcription factor, is found to promote the survival of newly formed neurons in the brain [58]. MEF2D is also responsible for influencing the number of excitatory synapses in an activity-dependent manner, thus indirectly neuronal excitability, which is a common factor for a migraine candidate gene. Phosphatase and actin regulator 1 (PHACTR1) gene is supposed to regulate the activity of PP1 (protein phosphatase 1), which further influences synaptic activity and morphology in migraine [59, 60]. Transforming growth factor β receptor 2(TGFBR2) is a serine-threonine kinase enzyme that is active in proliferation, and Astrotactin 2 (ASTN2) gene codes for a protein which is supposed to influence neuronal migration [61, 62]. In endothelial samples, only two gene products (TGFBR2 and MEF2D) exhibit moderate or greater expression.

In another study, which mainly reflects the known co-morbidity between migraine and cardiovascular diseases [63], it is reported that two of the 12 most proximal genes (TGFBR2 and PHACTR1) have also been related with cardiovascular traits: TGFBR2 mutations have been found to cause monogenic Marfan’s syndrome [64] and to be present in abdominal aortic aneurysms [65], while PHACTR1 is linked with early onset myocardial infarction [66]. Whereas TSPAN2 [67], MEF2D [68], TRPM8 [69], TGFBR2 [70], PHACTR1 [71], MMP16 [72], ASTN2 [62], and LRP1 [73] genes have been found to be functional in synaptic formation or its regulation. Mutations in PRDM16 have been linked to oxidative stress response in brain cells and those of AJAP1 in maintaining tissue borders.

Conclusions

Migraine is a common cause of headache, and early diagnosis and prompt treatment of migraine enhance the quality of life and prevent conversion of episodic migraine to chronic migraine. Single nucleotide polymorphism is a common form of allelic variation in human disease genes. SNPs may act as genomic biomarkers in search for variants that influence susceptibility to migraine. Diagnosis of migraine is still based on questionnaires and neuro-imaging mostly which should be replaced with various biomarkers. These biomarkers could easily be detected from saliva or blood samples of migraineurs by using biochemical or molecular methods. Various SNPs discussed in this review may reveal the phenotypic characters of migraineurs and have implications for functions of proteins coded by mutated genes. Each SNP may be genetically affected to a small group of migraineurs, but each one provides important information about migraine mechanism which can be further applicable to a wider population. These variants may further help in monitoring candidate drug response and in finding new targets for migraine pharmacotherapy. Hence, a better understanding of migraine genetics with rapid whole-genome sequencing in an individual could lead to personalize medicines in migraineurs.

Notes

Acknowledgements

I hereby acknowledge my co-authors for constantly encouraging, supporting, and helping me find the literature for this review article. The authors acknowledge the immense help received from the scholars whose articles are cited and included in the references of this manuscript. The financial support from the Union Grant Commission (UGC), New Delhi, India, is also highly acknowledged.

Authors’ contributions

All authors contributed equally in the preparation of the manuscript and read and approved the final version.

Funding

This work was supported by PDF given to Sukhvinder kaur by Union Grant Commission (UGC), New Delhi, India.

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

References

  1. 1.
    Kors E, Haan J, Ferrari M. Migraine genetics. Curr Pain Headache Rep. 2003;7:212–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Stewart WF, Shechter A, Rasmussen BK. Migraine prevalence: a review of population-based studies. Neurology. 1994;44(6 Suppl 4):S17–23.PubMedGoogle Scholar
  3. 3.
    Abu-Arefeh I, Russell G. Prevalence of headache and migraine in school children. BMJ. 1994;309:765–9.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Adams AM, Serrano D, Buse DC, Reed ML, Marske V, et al. The impact of chronic migraine: the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results. Cephalalgia. 2015;35(7):563–78.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Arslantas D, Tozun M, Unsal A, Ozbek Z. Headache and its effects on health-related quality of life among adults. Turk Neurosurg. 2013;23(4):498–504.PubMedGoogle Scholar
  6. 6.
    Stovner L, Hagen K, Jensen R, Katsarava Z, Lipton R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007;27:193–210.PubMedCrossRefGoogle Scholar
  7. 7.
    Russell MB, Ulrich V, Gervil M, Olesen J. Migraine without aura and migraine with aura are distinct disorders: a population-based twin survey. Headache. 2002;42:332–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Russell MB, Rasmussen BK, Fenger K, Olesen J. Migraine without aura and migraine with aura are distinct clinical entities: a study of four hundred and eighty-four male and female migraineurs from the general population. Cephalalgia. 1996;16:239–45.PubMedCrossRefGoogle Scholar
  9. 9.
    Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders, 3rd Edition (beta version). Cephalalgia. 2013;33(9):629–808.CrossRefGoogle Scholar
  10. 10.
    Colson NJ, Lea RA, Quinlan S, Griffiths LR. The role of vascular and hormonal genes in migraine susceptibility. Mol Genet Metab. 2006;88(2):107–13.PubMedCrossRefGoogle Scholar
  11. 11.
    Fernandez F, Colson NJ, Griffiths LR. Pharmacogenetics of migraine: genetic variants and their potential role in migraine therapy. Pharmacogenomics. 2000;8(6):609 (14).CrossRefGoogle Scholar
  12. 12.
    Maher BH, Griffiths LR. Identification of molecular genetic factors that influence migraine. Mol Genet Genomics. 2011;285(6):433–46.PubMedCrossRefGoogle Scholar
  13. 13.
    Colson N, Fernandez F, Griffiths L. Genetics of menstrual migraine: the molecular evidence. Curr Pain Headache Rep. 2010;14(5):389–95.PubMedCrossRefGoogle Scholar
  14. 14.
    Esserlind AL, Christensen AF, Le H, Kirchmann M, Hauge AW, et al. Replication and meta-analysis of common variants identifies a genome-wide significant locus in migraine. Eur J Neurol. 2013;20(5):765–72.PubMedCrossRefGoogle Scholar
  15. 15.
    Chasman DI, Schürks M, Anttila V, Vries B, Schminke U, et al. Genome-wide association study reveals three susceptibility loci for common migraine in the general population. Nat Genet. 2011;43(7):695–8.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Anttila V, Stefansson H, Kallela M, Todt U, Terwindt GM, et al. Genome-wide association study of migraine implicates a common susceptibility variant on 8q22.1. Nat Genet. 2010;42(10):869–73.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Gormley P, Anttila V, Winsvold BS, Palta P, Esko T, Pers TH, et al. Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine. Nat Genet. 2016;48:856–66.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Anttila V, Winsvold BS, Gormley P, Kurth T, Bettella F, McMahon G, et al. Genome-wide meta-analysis identifies new susceptibility loci for migraine. Nat Genet. 2013;45:912–7.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Pickrell JK, Berisa T, Liu JZ, Ségurel L, Tung JY, Hinds DA. Detection and interpretation of shared genetic influences on 42 human traits. Nat Genet. 2016;48:709–17.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Klimov E, Kondratieva N, Anuchina A, Skorobogatykh K, Azimova J, et al. Genetics of migraine - is there any progress? J Neurol Stroke. 2017;7(4):00245.CrossRefGoogle Scholar
  21. 21.
    Goadsby PJ, Classey JD. Glutamatergic transmission in the trigeminal nucleus assessed with local blood flow. Brain Res. 2000;875:119–24.PubMedCrossRefGoogle Scholar
  22. 22.
    Van den Maagdenberg AM, Haan J, Terwindt GM, Ferrari MD. Migraine: gene mutations and functional consequences. CurrOpinNeurol. 2007;20:299–305.Google Scholar
  23. 23.
    Martinez F, Castillo J, Rodriguez JR, Leira R, Noya M, et al. Neuroexcitatory amino acid levels in plasma and cerebrospinal fluid during migraine attacks. Cephalalgia. 1993;13:89–93.PubMedCrossRefGoogle Scholar
  24. 24.
    Goadsby PJ. Migraine pathophysiology. Headache. 2005;45(Suppl 1):S14–24.PubMedCrossRefGoogle Scholar
  25. 25.
    Lauritzen M. Pathophysiology of the migraine aura: the spreading depression theory. Brain. 1994;117(Pt 1):199–210.PubMedCrossRefGoogle Scholar
  26. 26.
    Andreou AP, Goadsby PJ. Therapeutic potential of novel glutamate receptor antagonists in migraine. Expert Opin Invest Drugs. 2009;18(6):789–803.CrossRefGoogle Scholar
  27. 27.
    Greenamyre JT, Young AB, Penney J. Quantitative autoradiographic distribution of l-[3H] glutamate-binding sites in rat central nervous system. J Neurosci. 1984;4(8):2133–44.PubMedCrossRefGoogle Scholar
  28. 28.
    Kai–Kai MA, Howe R. Glutamate-immunoreactivity in the trigeminal and dorsal root ganglia, and intraspinal neurons and fibers in the dorsal horn of the rat. Histochem J. 1991;23(4):171–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Peres MF, Zukerman E, SenneSoares CA, Alonso EO, Santos BF, et al. Cerebrospinal fluid glutamate levels in chronic migraine. Cephalalgia. 2004;24(9):735–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Rothrock JF, Mar KR, Yaksh TL, Golbeck A, Moore AC. Cerebrospinal fluid analyses in migraine patients and controls. Cephalalgia. 1995;15(6):489–93.PubMedCrossRefGoogle Scholar
  31. 31.
    Goyette P, Summer JS, Milos R, Ducan AM, Rosenblatt DS, et al. Human methylenetetrahydrofolatereductase isolation of cDNA, mapping and mutation identification. Nat Genet. 1994;7:195–200.PubMedCrossRefGoogle Scholar
  32. 32.
    Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydofolatereductase. Nat Genet. 1995;10:111–3.PubMedCrossRefGoogle Scholar
  33. 33.
    Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002;325:1202.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Coull BM, Malinow MR, Beamer N, Sexton G, Nordt F, et al. Elevated plasma homocysteine concentrations as a possible independent risk factor for stroke. Stroke. 1990;21:572–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Kelly PJ, Rosand J, Kistler JP, Shih VE, Silveira S, et al. Homocysteine, MTHFR 677C-->T polymorphism, and risk of ischemic stroke: results of a meta-analysis. Neurology. 2002;59:529–36.PubMedCrossRefGoogle Scholar
  36. 36.
    Schwaag S, Nabavi DG, Frese A, Husstedt IW, Evers S. The association between migraine and juvenile stroke: a case-control study. Headache. 2003;43:90–5.PubMedCrossRefGoogle Scholar
  37. 37.
    Donaghy M, Chang CL, Poulter NJ. Duration, frequency, recency, and type of migraine and the risk of ischaemic stroke in women of childbearing age. NeurolNeurosurg Psychiatry. 2002;73:747–50.CrossRefGoogle Scholar
  38. 38.
    Tzourio C, Iglesias S, Hubert JB, Visy JM, Alperovitch A, et al. Migraine and risk of ischaemic stroke: a case-control study. PMID. 1993;31:289–92.Google Scholar
  39. 39.
    Weisberg IS, Jacques FP, Selhub J, Bostom AG, Chen Z, et al. The 1298A→C polymorphism in methylenetetrahydrofolatereductase (MTHFR): in vitro expression and association with homocysteine. Atherosclerosis. 2001;156:409–15.PubMedCrossRefGoogle Scholar
  40. 40.
    Friedman G, Goldschmidt N, Friedlander Y, Ben-Yehuda A, Selhub J, et al. A common mutation A1298C in human methylenetetrahydrofolatereductase gene: association with plasma total homocysteine and folate concentrations. JNutr. 1999;129(9):1656–61.Google Scholar
  41. 41.
    Lillis AP, Duyn LB, Murphy-Ullrich JE, Strickland DK. LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol Rev. 2008;88(3):887–918.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Proudfoot CJ, Garry EM, Cottrell DF, Rosie R, Anderson H, et al. Analgesia mediated by the TRPM8 cold receptor in chronic neuropathic pain. CurrBiol. 2006;16(16):1591–605.CrossRefGoogle Scholar
  43. 43.
    Peier AM, Moqrich A, Hergarden AC, Reeve AJ, Andersson DA, et al. A TRP channel that senses cold stimuli and menthol. Cell. 2002;108(5):705–15.PubMedCrossRefGoogle Scholar
  44. 44.
    Dray A. Neuropathic pain: emerging treatments. Br J Anaesth. 2008;101(1):48–58.PubMedCrossRefGoogle Scholar
  45. 45.
    Biondi DM. Is migraine a neuropathic pain syndrome? Curr Pain Headache Rep. 2006;10(3):167–78.PubMedCrossRefGoogle Scholar
  46. 46.
    Seale P, Bjork B, Yang W, Kajimura S, Chin S, et al. PRDM16 controls a brown fat/skeletal muscle switch. Nature. 2008;15:961–7.CrossRefGoogle Scholar
  47. 47.
    Takahata M, Inoue Y, Tsuda H, Imoto I, Koinuma D, et al. SKI and MEL1 cooperate to inhibit transforming growth factor-beta signal in gastric cancer cells. J BiolChem. 2009;15:3334–44.Google Scholar
  48. 48.
    Sherman EA, Strauss KA, Tortorelli S, Bennett MJ, Knerr I, et al. Genetic mapping of glutaricaciduria, type 3, to chromosome 7 and identification of mutations in c7orf10. Am J Hum Genet. 2008;83:604–9.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Marlaire S, Van Schaftingen E, Veiga-da-Cunha M. C7orf10 encodes succinate-hydroxymethylglutarate CoA-transferase, the enzyme that converts glutarate to glutaryl-CoA. J Inherit Metab Dis. 2004;37(1):13–9.CrossRefGoogle Scholar
  50. 50.
    Rozanov DV, Hahn-Dantona E, Strickland DK, Strongin AY. The low density lipoprotein receptor-related protein LRP is regulated by membrane type-1 matrix metalloproteinase (MT1-MMP) proteolysis in malignant cells. J BiolChem. 2004;279:4260–8.Google Scholar
  51. 51.
    Borrie SC, Baeumer BE, Bandtlow CE. The Nogo-66 receptor family in the intact and diseased CNS. Cell Tissue Res. 2012;349:105–17.PubMedCrossRefGoogle Scholar
  52. 52.
    Schreiner A, Ruonala M, Jakob V, Suthaus J, Boles E, et al. Junction protein shrew-1 influences cell invasion and interacts with invasion-promoting protein CD147. MolBiol Cell. 2007;18:1272–81.Google Scholar
  53. 53.
    Lafleur MA, Xu D, Hemler ME. Tetraspanin proteins regulate membrane type-1 matrix metalloproteinase-dependent pericellular proteolysis. MolBiol Cell. 2009;20(7):2030–40.Google Scholar
  54. 54.
    Fimia GM, De Cesare D, Sassone-Corsi P. A family of LIM-only transcriptional coactivators: tissue-specific expression and selective activation of CREB and CREM. Mol Cell Biol. 2000;20:8613–22.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Dash PK, Hochner B, Kandel ER. Injection of the cAMP-responsive element into the nucleus of Aplysia sensory neurons blocks long-term facilitation. Nature. 1990;345:718–21.PubMedCrossRefGoogle Scholar
  56. 56.
    Lee YS, Silva AJ. The molecular and cellular biology of enhanced cognition. Nat Rev Neurosci. 2009;10:126–40.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Freilinger T, Anttila V, De VB, Malik R, Kallela M, et al. Genome-wide association analysis identifies susceptibility loci for migraine without aura. Nat Genet. 2012;15:777–82.CrossRefGoogle Scholar
  58. 58.
    Flavell SW, Cowan CW, Kim TK, Greer PL, Lin Y, et al. Activity-dependent regulation of MEF2 transcription factors suppresses excitatory synapse number. Science. 2006;15:1008–12.CrossRefGoogle Scholar
  59. 59.
    Allen PB, Greenfield AT, Svenningsson P, Haspeslagh DC, Greengard P. Phactrs 1–4: a family of protein phosphatase 1 and actin regulatory proteins. ProcNatlAcadSci U S A. 2004;15:7187–92.CrossRefGoogle Scholar
  60. 60.
    Greengard P, Allen PB, Nairn AC. Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron. 1999;15:435–47.CrossRefGoogle Scholar
  61. 61.
    Lin HY, Wang XF, Ng-Eaton E, Weinberg RA, Lodish HF. Expression cloning of the TGF-beta type II receptor, a functional transmembrane serine/threonine kinase. Cell. 1992;15:775–85.CrossRefGoogle Scholar
  62. 62.
    Wilson PM, Fryer RH, Fang Y, Hatten ME. Astn2, a novel member of the astrotactin gene family, regulates the trafficking of ASTN1 during glial-guided neuronal migration. J Neurosci. 2010;15:8529–40.CrossRefGoogle Scholar
  63. 63.
    Schürks M, Rist PM, Bigal ME, Buring JE, Lipton RB, et al. Migraine and cardiovascular disease: systematic review and meta analysis. BMJ. 2009;339:b3914.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Mizuguchi T, Collod-Beroud G, Akiyama T, Abifadel M, Harada N, et al. Heterozygous TGFBR2 mutations in Marfan syndrome. Nat Genet. 2004;36:855–60.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Biros E, Walker PJ, Nataatmadja M, West M, Golledge J. Downregulation of transforming growth factor, beta receptor 2 and Notch signaling pathway in human abdominal aorticaneurysm. Atherosclerosis. 2012;221:383–6.PubMedCrossRefGoogle Scholar
  66. 66.
    Kathiresan S, Voight BF, Purcell S, Musunuru K, Ardissino D, et al. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet. 2009;41:334–41.PubMedCrossRefGoogle Scholar
  67. 67.
    Terada N, Baracskay K, Kinter M, Melrose S, Brophy PJ, et al. The tetraspanin protein, CD9, is expressed by progenitor cells committed to oligodendrogenesis and is linked to beta1 integrin, CD81, and Tspan-2. Glia. 2002;40:350–9.PubMedCrossRefGoogle Scholar
  68. 68.
    Flavell SW, Kim TK, Gray JM, Harmin DA, Hemberg M, et al. Genome-wide analysis of MEF2 transcriptional program reveals synaptic target genes and neuronal activity-dependent polyadenylation site selection. Neuron. 2008;60:1022–38.PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Tsuzuki K, Xing H, Ling J, Gu JG. Menthol-induced Ca2+ release from presynaptic Ca2+ stores potentiates sensory synaptic transmission. J Neurosci. 2004;24:762–71.PubMedCrossRefGoogle Scholar
  70. 70.
    Diniz LP, Almeida JC, Tortelli V, Vargas Lopes C, Setti-Perdigão P, et al. Astrocyte-induced synaptogenesis is mediated by transforming growth factor beta signaling through modulation of D-serine levels in cerebral cortex neuron. J BiolChem. 2012;287(49):41432–41,445.Google Scholar
  71. 71.
    Allen PB, Greenfield AT, Svenningsson P, Haspeslagh DC, Greengard P. Phactrs. 1–4: a family of protein phosphatase 1 and actin regulatory proteins. ProcNatlAcad Sci USA. 2004;101:7187–92.CrossRefGoogle Scholar
  72. 72.
    Ferraro GB, Morrison CJ, Overall CM, Strittmatter SM, Fournier AE. Membrane-type matrix metalloproteinase-3 regulates neuronal responsiveness to myelin through Nogo-66 receptor 1 cleavage. J BiolChem. 2011;286:31418–24.Google Scholar
  73. 73.
    May P, Rohlmann A, Bock HH, Zurhove K, Marth JD, et al. Neuronal LRP1 functionally associates with postsynaptic proteins and is required for normal motor function in mice. Mol Cell Biol. 2004;24:8872–83.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© The Author(s) 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  1. 1.Gene expression Lab, Department of BiosciencesJamia Millia IslamiaNew DelhiIndia
  2. 2.Department of BiosciencesJamia Millia IslamiaNew DelhiIndia
  3. 3.Department of PhysiologyESIC Medical College & HospitalFaridabadIndia
  4. 4.NC Medical College & HospitalPanipatIndia

Personalised recommendations